Year: 2025
Type: article
Abstract: The nasal allergen challenge (NAC) is a valuable diagnostic tool for both clinicians and researchers in the field of allergy and its management. In Europe, an aqueous extract Aquagen SQ (ALK-Abelló) was historically the most widely used solution for this purpose. Its production ceased in 2019, creating a gap in available resources. This clinical trial evaluated the feasibility of using dissolved birch pollen tablets, ITULAZAX 12-SQ Bet (ALK-Abelló) tablets as an alternative for NAC. A total of 69 participants with confirmed birch pollen allergy and 20 healthy controls underwent NAC using either dissolved ITULAZAX, dissolved placebo tablets, or a 0.9% saline solution. The primary objective was to assess the sensitivity of NAC with dissolved ITULAZAX. The method demonstrated a sensitivity of 96% and a specificity of 95%. These findings support the use of dissolved ITULAZAX as a reliable and accessible allergen source for nasal allergen challenges in both clinical practice and research.
Source: Scientific Reports
Authors: Eirini Paziou, Karin Jamil Ali, Susanna Kumlien Georén, Agneta Karlsson, Emma Nilsson, Laila Hellkvist, Lars Olaf Cardell
Institutions: Karolinska University Hospital, Karolinska Institutet
Language: English
Subfield: Immunology and Allergy
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,690
Funder: Karolinska Institutet
OpenAlex ID: W4416075020